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Abstract
Glioblastoma multiform (GBM) is known as an aggressive glial neoplasm. Recently incorporation of mesenchymal stem 
cells with anti-tumor drugs have been used due to lack of immunological responses and their easy accessibility. In this study, 
we have investigated the anti-proliferative and apoptotic activity of atorvastatin (Ator) in combination of mesenchymal stem 
cells (MSCs) on GBM cells in vitro and in vivo. The MSCs isolated from rats and characterized for their multi-potency 
features. The anti-proliferative and migration inhibition of Ator and MSCs were evaluated by MTT and scratch migration 
assays. The annexin/PI percentage and cell cycle arrest of treated C6 cells were evaluated until 72 h incubation. The animal 
model was established via injection of C6 cells in the brain of rats and subsequent injection of Ator each 3 days and single 
injection of MSCs until 12 days. The growth rate, migrational phenotype and cell cycle progression of C6 cells decreased 
and inhibited by the interplay of different factors in the presence of Ator and MSCs. The effect of Ator and MSCs on ani-
mal models displayed a significant reduction in tumor size and weight. Furthermore, histopathology evaluation proved low 
hypercellularity and mitosis index as well as mild invasive tumor cells for perivascular cuffing without pseudopalisading 
necrosis and small delicate vessels in Ator + MSCs condition. In summary, Ator and MSCs delivery to GBM model provides 
an effective strategy for targeted therapy of brain tumor.
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TGF-β1  Transforming growth factor-β1
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Introduction
Within a comparison view to the last global cancer statistics, 
an increasing trend into the prevalence of central nervous 
system (CNS) tumors and also its related death has been 
observed [1–4]. In this regard, the CNS tumors respectively 
show 1.6 and 2.5 percentages of all new cancer cases and 
mortalities just in 2018 [4]. Among these, glioblastoma 
multiform (GBM) as one of the most extensive and com-
mon type of the CNS malignancies holds poor therapeutic 
responses and also short median survival [1, 5–7]. Although 
multimodal aggressive therapies have been developed in 
order to the treatment of GBM cases. It should be noted 
that GBM patient’s median survival is not much more than 
18 months after the diagnosis. Local radiotherapy and also 
systemic chemotherapy in combination of surgical resection 
are the main conventional GBM therapeutic approaches [4, 
7–9]. However, due to the high-raise of mortality in GBM 
patients and the low efficiency of conventional medications, 
developing of the new and safe therapeutic strategies with 
a more anti-tumoral efficacy are required [4, 6–9]. It has 
clearly understood that the GBM progression and corre-
spondingly mutual patient’s therapeutic responses are sig-
nificantly affected by the GBM specific microenvironment 
[10–14]. Generally, the GBM microenvironments appear 
through secretion of several pro-inflammatory cytokines as 
well as hypoxic condition [15–18]. In this process, as the 
main pro-inflammatory microenvironment mediators includ-
ing interleukin-1β (IL-1β), interleukin-6 (IL-6), and also 
interleukin-8 (IL-8) increase by activation of their related 
downstream targets such as the JAK-STAT, PI3K-AKT, and 
mitogen-activated protein kinase (MAPK) signaling path-
ways [7, 9, 19–21]. These conditions cause GBM cell pro-
liferation, invasion, migration and also tumor angiogenesis 
within the brain region [3, 5–7, 19, 21]. Herein, it has been 
suggested that the GBM specific microenvironment compo-
nents such as anti-GBM drugs and also their related inhibit-
ing downstream pathways activated by stem cells are able 
to be as a high potent targets in order to develop the novel 
GBM therapeutic approaches [4, 6, 8, 22–24].
Nowadays, mesenchymal stem cells (MSCs) have been 
introduced as one of the effective mammalian’s cellular pop-
ulations to manage the malignant tissues behaviors [6, 8, 22, 
23]. As a type of multipotent cells, beside their self-renewal 
and differentiation potential, it has been demonstrated that 
the MSCs have ability to express an array of paracrine/auto-
crine factors through secretion of anti-inflammatory mol-
ecules [6, 22, 23]. Previous observations described that the 
direct interaction of MSCs within some tumor’s complicate 
microenvironment, such as the GBM, can actively regu-
late the tumor’s immunological responses and in following 
inhibit the malignancy progression [6, 10, 12, 22, 23, 25]. 
Besides the modulation of the GBM inflammatory micro-
environment, it resembles that the interactions of the MSCs 
through activation of tumor necrosis factor-related apopto-
sis-inducing ligand (TRAIL), as one of the central cell death 
ligands, progress apoptosis process into cancerous cells [6, 
10, 12, 22, 23, 25].
On the other side, during the past decades, statin fam-
ily, as kinds of HMG-CoA inhibitors have been found an 
extensive medical application in treatment of diverse types 
of disorders and diseases [3, 9, 11, 16, 20, 21]. For instance, 
atorvastatin (Ator) as a kind of the statins, with its impact-
ful role in curing some types of cardiovascular disease has 
known as an appropriate therapy approach in inhibition of 
photogenic vessels and angiogenesis development [3, 9, 11, 
16, 20, 21]. It seems that Ator is stimulus anti-angiogenic 
response, notably into the inflammatory microenvironment 
which may be formed by down-regulation of some core 
antigenic factors including the vascular endothelial growth 
factor (VEGF), tumor necrosis factor-α (TNF-α), and also 
transforming growth factor-β1 (TGF-β1) [3, 9, 16, 21, 26]. 
Subsequently, it is expected that utilizing variety of statins 
may be a useful medication for hindering the malignant tis-
sues progression [3, 9, 16, 21]. Accordingly, the main goal 
of our study was evaluation of beneficial effects of Ator in 
high-dose as well as MSCs on anti-GBM activities in experi-
mental rat GBM models.
In the present study we aimed to evaluate the anti-pro-
liferative apoptotic and cell cycle arrest effects of Ator and 
MSCS on C6 glioma cell line in vitro and their anti-tumor 
impact in vivo. The cellular proliferation, scratch migration, 
annexin/PI cell cycle and cell cycle arrest were evaluated 
for treated C6 cells with Ator and MSCs. The GBM model 
was established and Ator and MSCs were implanted in rat 
model until 12 days. The hematoxin and eosin staining of 
brain tissue and tumor size was evaluated to reveal anti-
tumor activity of these substrates.
Materials and methods
Materials
Minimum essential medium eagle-alpha modifica-
tion (α-MEM), dulbecco’s modified eagle medium 
(DMEM), fetal bovine serum (FBS) and penicillin-
streptomycin were purchased from Gibco Life Tech-
nologies (Grand Island, NE, USA). Atorvastatin 
([R-(R*, R*)-2-(4-Fluorophenyl)-ß, d-dihydroxy-5-(1-
methylethyl)-3-Phenyl-4-(Phenylamino)-Carbonyl]-1-H-
Pyr- role-1-heptanoic acid), dimethyl sulfoxide (DMSO), 
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3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT), trizol solution and 2 × Real Rime SYBER 
GREEN master mix, phosphate-buffered saline (PBS), keta-
mine and xylazine were purchased from Sigma-Aldrich (St. 
Louis, MO). Terminal deoxy- nucleotidyl transferase medi-
ated dUTP nick-end labeling (TUNEL) Kit was obtained 
from (Roche, Mannheim, Germany).
Study design
This study was conducted on four series of experiments 
including: first group, GBM model without any treatment, 
second group, the effect of Ator on glioblastoma cancer 
cell lines; third group, anti-tumorigenic and anti-metastatic 
effects of MSCs and fourth group simultaneous incorpora-
tion of Ator and MSCs on histopathology of animal model 
(Fig. 1).
Animals
The male Wistar rats (200–220 g) of 2 months of age were 
purchased from Pasteur Institute (Tehran, Iran). Those 
preserved in ventilated and room temperature controlled 
at 23–25 °C with a 12 h light/dark cycle and had access 
standard food pellets and water. Animals use and care 
were approved with national ethics committee of Tehran 
University of Medical Sciences (ethical code: IR.TUMS.
VCR.REC.13,951,833) and were performed in accordance 
with the university’s guidelines. Furthermore, all animal 
experiments comply with the National Institutes of Health 
guide for the care and use of laboratory animals (NIH Pub-
lications No. 8023, revised 1978).
Fig. 1  Schematic of study design for evaluation of atorvastatin (Ator) and mesenchymal stem cells (MSCs) impact in rat glioblastoma multiform 
(GBM) model
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Cell culture
Bone marrow mesenchymal stem cells (MSCs) were isolated 
from wistar rats according previously described protocol 
[27]. Briefly, the wistar rats aged 6–8 weeks were terminated 
by cervical dislocation and soaked in 70% (v/v) ethanol and 
then the animal was transferred to a new dish. Tibias, femurs, 
and humeri were dissected by cutting at the joints, and the 
bones were transferred to a 100-mm sterile culture dish with 
10 mL complete α-MEM medium on ice. Then two ends 
of femurs and tibias were cut open with a scissor and then 
5 ml DMEM in syringe, flush the marrow into a 50 mL tube 
by inserting the 22-G needle to one open end of the bone. 
After that, marrows were obtained, re-suspended cells and 
were passed it through a 40 µm cell strainer to discard the 
blood aggregates as well as the bone debris. The cells were 
harvested via centrifugation process and were sub-cultured 
in 100 mm culture dish in a 37 °C and 5%  CO2 incubator for 
2 weeks. Medium was changed every 2 ~ 3 days. All samples 
were processed within 30 minutes following animal death to 
ensure high cell viability. The C6 cell line were purchased 
from the Cell Bank of the Pasteur Institute of Iran (Tehran, 
Iran). These cells maintained in DMEM medium containing 
10% FBS and 1% penicillin-streptomycin.
MSC phenotype
The expression of cell surface protein was investigated by 
flow cytometry technique. The MSCs were trypsinized and 
incubated with specific PE- or fluorescein isothiocyanate-
conjugated (FITC)-conjugated anti-CD31, CD45, CD90, and 
CD105 fluorescent dye conjugated anti-human antibodies for 
30 min at 4 °C in a dark place. Afterwards, the cells were 
washed and re-suspended in PBS. The suspended cells were 
applied in FACS caliber (BD Biosciences) for cell surface 
protein expression measurement. Flowcytometric data was 
analyzed using FlowJo software (FlowJo, LLC). Positive and 
negative controls were also evaluated in each run. Further-
more, to confirm the mesenchymal phenotype of isolated 
cells, these cells were differentiated into osteogenic and 
adipogenic lineages as previously described [28]. The cells 
were sub-cultured and passage-3 MSCs were used for all 
experiments.
MTT assay
MTT assay was performed to measure anti-proliferation 
impacts of Ator and MSCs by MTT Kit on GBM tumor cell 
model [28]. Concisely, C6 cell lines at 2 × 104 cells/48 well-
plates were planted in for 12 h. Then medium was changed 
to fresh DMEM medium supplemented with Ator 100 µM 
and MSCs in equal density of C6 cells using 48-transwell 
plates with a polycarbonate filter (8-µm pore size, Millipore) 
until additional 72 h. At the indicated time points, 200 µL 
MTT solution 5 mg/mL was added in each well and incu-
bated in a 5%  CO2 and 37 °C. After 4 h, the medium was 
removed and insoluble purple formazan product was dis-
solved by DMSO for 15 min. The absorbance was measured 
at 570 nm was determined by a microplate reader (EL340 
Bio-Tek Instruments, Hopkinton, MA).
Cell migration assay
In this method, the C6 cells were seeded at a density of 
2 × 104 cells/cm2 were incubated for 24 h in a 48 well-plates 
[29]. The scratch was created on cells with 90% confluent 
monolayer mechanically with a sterile plastic yellow tip to 
make a uniform cell free area. Detached cells and debris 
were washed away with PBS. After that, cells were treated 
and incubated with Ator 100 µM or equal density of MSCs 
using 48-transwell plates as well as combination of both 
of Ator 100 µM and MSCs MSCs using transwell plate. 
Cell motility and migration into the wound area were moni-
tored for 48 h using an optical microscope (Nikon Eclipse 
TE2000-S, Germany). The microphotographs were cor-
related and the number of cells migrated into the scratch 
was counted for quantitative analysis using Image J analysis 
software.
Cell cycle assays
The C6 cells at 1 × 105 cells/well were seeded in 6-transwell 
plates. After 24 h, attached cells were treated with different 
conditions including Ator 100 µM or MSCs using 6-tran-
swell plates in equal density of seeded C6 cells as well as a 
combination of both of Ator and MSCs using transwell plate. 
After another 48 h, the conditioned medium containing float-
ing C6 cells was collected and combined with adherent cells 
that were detached by brief trypsinization. The harvested 
cells were rinsed with ice-cold PBS, re-suspended in 0.5 mL 
of 70% ethanol overnight. Then, the cells were pelleted via 
centrifugation at 2000 rpm/5 min, re-suspended in 500 µL of 
PBS containing 50 µg RNase A and 5 µg propidium iodide 
(PI), and incubated in dark at 25 °C for 0.5 h. The cells were 
fully re-suspended and cell cycle was analyzed using a BD 
Accuri C6 flow cytometer (BD Biosciences, CA, USA). The 
obtained records were processed using AXP acquisition and 
analysis software.
Annexin‑PI assay
Annexin-PI assay was used to detect the percentage of C6 
cells in apoptosis phase which induced by Ator and MSCs 
likewise cell cycle study. After 48 h treatment of C6 cells 
with Ator and MSCs, the annexin in and PI reagent were 
added to harvested C6 cells and kept in the dark on ice for 
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30 min. Then C6 cells were washed via PBS and centrifu-
gation to removed non-reacted fluorophore molecules. The 
fluorescence of labeled cells was measured using a flow 
cytometer.
GBM model establishment
Twenty four wistar rats were obtained, weighed and divided 
into four groups to study in vivo phase (Fig. 1). To estab-
lishment of the GBM, the rats were anaesthetized with ket-
amine-xylazine mixture (120 mg/kg/IP) and positioned in a 
stereotaxic instrument (Stoelting, Hertfordshire, UK). The 
stereotaxic coordinates of the intracranial injection were 
AP = + 1.6 mm to bregma, ML = − 2 mm lateral to bregma, 
and DV = − 6 mm ventral. Animals were received C6 rat gli-
oma cells at 5 × 104 density in 2.5 µL DMEM through a sin-
gle microinjection into the right stratum using 10 µL syringe 
(Hamilton, Bonaduz, Switzerland), at a constant rate of 
0.5 µL/min. The experimental conditions were (I) GBM ani-
mal model (Control group), (II) GBM animal model treated 
with Ator group, (III) GBM animal model treated with MSCs 
group, and (IV) GBM animal model treated with combination 
of Ator and MSCs. In group IV 3 days after post-implantation 
of MSCs 1 × 106 cells, rats were treated with Ator 100 µM 
three times with a 3-day interval. As shown in Fig. 1, animals 
were treated with MSCs 1 × 106 cells by a single intracerebral 
injection, and an intraperitoneal injection of Ator 100 µM 
with an interval of 3 days between injections, according to 
the schematic illustration of the in vivo antitumor process.
Antitumor efficacy assessment
The relative body weight and tumor size quantification were 
carried out during the treatment and end of study respec-
tively. Tumor volume was calculated by summing the seg-
mented regions. The malignant and normal tissue regions 
were completely distinguished by visual observations. The 
malignant tissues were dissected using a scalpel blade and 
weighed.
Histological assay
After treatment for 12 days, the rats were euthanized and the 
tumors were collected and fixed in 4% PBS buffered para-
formaldehyde followed by passage and embedding in paraf-
fin. In order to perform the hematoxylin and eosin (H & E) 
staining, paraffin blocks were sectioned by 5 µm thickness. 
Slides were studied at the microscopic level (OLYMPUS-
BX51 microscope), then an Olympus-DP12 camera was 
used to take digital photos.
Quantitative real‑time polymerase chain reaction
In order to define the expression level of VEGF, BCL2, 
BAX, IL1-β, BDNF, GFAP and KI67 genes, Trizol solu-
tion (Invitrogen, USA) was used to extract total RNA 
from tissues according to the manufacturer’s instruc-
tions. Afterward, cDNA was synthesized by RevertAid 
first-strand cDNA synthesis kit (Thermo Scientific Fer-
mentas, USA), according to the manufacturer’s instruc-
tions. Primers for real-time PCR were designed using 
Beacon Designer 7 software. The primer sequences 
information presented in Table.1. Quantitative RT-PCR 
(qRT-PCR) was performed on cDNAs using Rotor-Gene 
Q 2plex HRM platform real-time PCR system (Corbett 
Life Science). The relative expression levels of anti- and 
pro- apoptotic gens were evaluated in comparison with 
GAPDH as an endogenous control gene. The RT-PCR 
reactions were done in duplicate, as performed in previous 
studies [3, 17]. Rotor-gene Q sequence detection system 
determined the threshold cycle (CT) values. Comparative 
threshold cycle (2 − ΔΔCT) method was used in order to 
analyze the data.
Statistical analysis
All experiments were carried out in triplicate for each con-
dition. The data are shown as means ± standard deviation 
(SD). Statistical analysis was done by Minitab 18 software 
(Minitab, Inc., State College, USA). Significant differ-
ences are expressed as *p < 0.05, **p < 0.01, ***p < 0.001 
and #p > 0.05 in bar graphs.
Table 1  List of primer couples generated for real-time RT-PCR
Gene Primer sequence
VEGF F AAG ACC GAT TAA CCA TGT CA
R ATG TCA GGC TTT CTG GAT TA
BCL2 F GTG GCC TTC TTT GAG TTC GG
R CAC AGA GCG ATG TTG TCC AC
BAX F CAT CCA CCA AGA AGC TGA GC
R GCA ATC ATC CTC TGC AGC TC
IL1-β F TTC AGG AAG GCA GTG TCA CT
R CGT CTT GGT TTT GCA GCT CT
BDNF F AGC CTC CTC TGC TCT TTC TG
R CGC CGA ACC CTC ATA GAC AT
GFAP F TAA GCG TCC ATC CTC CTG TTT GAA AG
R ACA CTA ATC GAA GGC ACT CCA 
KI67 F ATC AGA CAC AGT GAC AGG CA
R TTG CAT GCT CGT GAC CTT CT
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Results
The cells were mostly negative for CD31 at 11% and CD45 
at 41% indicating nearly absence of the hematopoietic and 
endothelial cell markers among the isolated cells (Fig. 2a). 
Additionally, the cytofluorometric results revealed the 
expression of distinguished MSC CD markers includ-
ing CD90 and CD105 antigens more than 90% (Fig. 2a). 
Moreover, the multi-lineage differentiation potential of 
isolated MSCs, as the major characteristic of mesoder-
mal-originated cells, showed a number of lipid droplets as 
well as major calcium deposition after the adipogenic and 
osteogenic inductions respectively (Fig. 2b). Flow cytom-
etry analysis of the MSCs with specific antibodies revealed 
the expression of prominent MSC markers including CD90 
and CD105 and the low level of endothelial cell marker 
CD31 as well as hematopoietic stem cell marker CD45. 
Collectively, flow cytometry and differentiation potential 
of isolated cells verified the extracted bone MSC charac-
teristics of the MSCs at the third and fourth passage [28, 
30, 31].
Fig. 2  a Flow cytometry his-
tograms of MSCs stained with 
fluorescein conjugated antibody. 
Black: MSCs without staining 
with corresponding fluorescein 
conjugated antibody; red: MSCs 
stained with corresponding 
fluorescein conjugated antibody. 
b Isolated MSCs differentiated 
into adipocytes and osteoblasts. 
(Color figure online)
7789Molecular Biology Reports (2020) 47:7783–7795 
1 3
MTT assay
The growth potential of C6 cell after treating with Ator and 
MSCs was evaluated by cellular morphology observation 
and MTT assay. As can be seen, C6 cell viability increased 
in control group by increasing time of culture in spindle-
shaped and cells were totally spread with cytoplasmic exten-
sion (Fig. 3a). Besides, cellular morphology was changed 
to spheroid-shape and growth suppression was observed by 
microscopic observation of cells during extended time of 
culture compared with non-treated condition. Meanwhile, 
high cell-free area was observed in treated condition with 
Ator and MSCs after 72 incubation time (Fig. 3a). The C6 
cells were entirely covered plate surface in non-treated con-
dition as a negative control group. An interesting point from 
Fig. 3 is that C6 cell viability significantly decreased in a 
time-depended manner with incorporation of Ator as well 
as MSCs (Fig. 3a and b). There were no substantial differ-
ences among cellular viability of Ator and MSCs groups 
at 24 h after incubation. The lower cell viability in Ator 
and Ator + MSCs conditions compared with alone MSCs 
condition was obtained at 72 h incubation (Fig. 3a and b). 
Recent studies show that Ator and MSCs affect mitochon-
drial functions of cells which has an important role in cell 
survival [17, 21, 23, 26, 32]. We found that Ator when com-
bined with MSCs had more synergistic cytotoxicity on GBM 
cells about 60% lower cellular growth compared with single 
treated conditions with Ator or MSCs after 72 h.
Migration assay
Scratch migration of C6 cells was evaluated according to 
the method described previously [29]. Figure 4 shows the 
morphology of C6 cells cultured on culture dish. We made 
successfully uniformly sized wounds of approximately 
400 µm in width. The inhibitory effect of Ator, MSCs and 
Ator + MSCs on C6 cell migration was studied. The C6 
cells covered the scratched area (cell-free area) of culture 
dish in control condition after 48 h of incubation (Fig. 4). 
Meanwhile, the cells covered only 54%, 73% and 43% of 
the scratched area of Ator, MSCs and Ator + MSCs con-
ditions (Fig. 4a and b) (P < 0.05). The results indicated 
Fig. 3  Cell viability of C6 Cells treated with Ator, MSCs and Ator + MSCs after 72 h. a Morphology observation of seeded C6 cells and b MTT 
assay histogram after 24 and 72 h treatment with Ator and MSCs. The results were expressed as mean ± SD
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that Ator and Ator + MSCs had significant inhibitory effect 
on the invasion and migration of C6 cells (p < 0.05). In 
addition, cell migration level increased by increase of 
incubation time in experimental conditions proved that 
cell migration inhibition by Ator and MSCs was dose-
time-dependent. Number of migrated and attached cells 
in the presence of MSCs was higher to some extent in 
comparison with Ator which proved effectiveness of Ator 
as revealed by cell proliferation study. Meanwhile, the cel-
lular cytoplasm was condensed and cell size decreased 
from spindle shape to spheroid compared with control con-
dition which cells were totally spread and cells had a long 
spindle-shaped morphology [3, 18, 19, 23]. There was no 
significant difference in C6 cell morphologies among these 
three conditions treated with tumor cell inhibitors during 
48 h of culture. These data suggest that by Ator and MSCs 
treatment could obtain migration suppression and prolif-
eration inhibition on C6 glioma cells. Whereas cultures 
of primary glial cells are observed in normal morphology 
and high migration rate when subculture in conventional 
culture system without exposure to anti-cancerous drug 
or stem cells.
Annexin/PI and cell cycle
It is well known that the mitochondrial membrane loss 
mostly linked to the initiation and activation of apoptotic 
process in cells. The mitochondrial membrane damage and 
dissipation regulates intensification of apoptogenic factors 
and finally cell death [8, 9, 18, 19, 21, 23, 33]. In this study, 
apoptosis and necrosis degrees of C6 cells which induced by 
presence of Ator and MSCs were evaluated and compared 
non-treated C6 cells as a GBM model. The percentage of C6 
cells in apoptosis and necrosis phases was assessed by flow-
cytometry for Ator, MSCs and Ator + MSCs experimental 
conditions (Fig. 5a and b). Early and late apoptosis rates of 
C6 cells were 4% and 3% respectively in non-treated condi-
tion (Control) (Fig. 5a and b). The early apoptosis and late 
apoptotic cells were respectively 17% and 3.5% for MSC 
and 27% and 23% for Ator condition (Fig. 5a and b). As can 
be seen in Fig. 5a and b the treated cells by Ator + MSCs 
had higher late apoptosis level and necrosis level compared 
to cells treated by Ator and MSCs as well as control group. 
For C6 cells treated with Ator + MSCs, majority of cells 
were in early and late apoptosis condition at 30% and 39% 
Fig. 4  Migration of C6 cells after treatment with Ator, MSCs in transwellplate and combination usage of Ator and MSCs for 48 h
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respectively (Fig. 5a and b). These results show that in the 
presence of Ator and Ator + MSCs were able to induce apop-
tosis faster in C6 cells as seen by the large amount of late 
apoptotic cells and diminished cell viability (Fig. 5a and b).
Evaluation of cell cycle arrest
To investigate whether Ator and MSCs suppressed can-
cer cell proliferation through cell cycle arrest, we treated 
the C6 cells with Ator, MSCs and analyzed the cell cycle 
distribution by flow cytometry. Figure 5c and d show the 
histograms and percentage of cells in each phase of the cell 
cycle which were categorized into G1/G0, S, and G2/M 
phases. As can be seen form Fig. 5c and d utilization of 
Ator, MSCs and Ator + MSCs lead to stimulating G0/G1 
cell cycle arrest and significant accumulation of C6 cells 
in G1/G0 phase of the cell cycle. The highest rate of G1/
G0 arrest was found for Ator and Ator + MSCs conditions 
lower than 10%. Whereas, Ator and Ator + MSCs decreased 
cell population in the  G2/M and S phases of cell cycle were 
Fig. 5  Flowcytometry assay to evaluate the effects of the MSCs, Ator 
and Ator + MSCs on the C6 cell apoptosis induction which compared 
with non-treated condition. a Histograms of harvested and stained 
C6 cells b Comparison of C6 cells death rates after 72 h treatment. 
Harvested C6 cells were stained with FITC-conjugated annexin V 
and propidium iodide and analyzed by the flowcytometry whereas 
annexin V and PI identify viable cells (annexin V−, PI−), early 
apoptotic cells (annexin V+, PI−), late apoptotic or necrotic cells 
(annexin V+, PI+) and necrotic cells (annexin V−, PI+). c Cell cycle 
distribution of C6 cells in different conditions including non-treated 
and treated by Ator, MSCs and combination of Ator with MSCs d 
Quantitative analysis of different cell phase populations. (Color figure 
online)
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about ∼2–4 times lesser than that of alone MSCs and non-
treated conditions (Fig. 5c and d). These results confirmed 
that the Ator and MSCs incorporation properly persuaded 
C6 cell arrest in the G0/G1 phase of the cell cycle [6, 8, 9, 
16, 19, 21, 23].
Real‑time polymerase chain reaction analysis
Apoptosis is mechanism in cell fate and tumor progression 
through alteration of anti- or pro apoptotic genes which 
could lead cell death [6, 8, 9, 16, 19, 21, 23]. We have meas-
ured several family of proteins includes apoptosis-related 
molecules including VEGF, BCL2, BAX, IL1-β, BDNF, 
KI67 genes for treated C6 cells with Ator and MSCs [6, 
8, 9, 16, 19, 21, 23]. Meanwhile, both of Ator and MSCs 
suppressed expression of VEGF, BAX and BDNF rates 
(Fig. 6a). The BCL2, IL1-β, GFAP and KI67 levels in C6 
tumor cells exposed with Ator and MSCs significantly acti-
vated compared to control sample (Fig. 6a). The expression 
of VEGF and PDGF especially at Ator and Ator + MSCs 
conditions were more than 2.4 times lower than control sam-
ple (Fig. 6a). The VEGF and PDGF upregulations are asso-
ciated to tumor cell development and progression through 
tumor angiogenesis and growth of blood vessels. Therefore, 
inhibition of VEGF and PDGF signaling not only blocks 
angiogenesis in tumors but can also destroy tumor vessels 
through suppression of cell proliferation and migration [3, 
7, 15, 18]. The VEGF and PDGF proteins in treated condi-
tions reflect drug and MSCs activity for tumor inhibition. 
Furthermore, it is well-know that BCL2 and BAX have to 
play cardinal roles in regulating mitochondrial translocation 
and dysfunction as well as oligomerization [3, 7, 15, 18, 21]. 
The BCL2 gene as an antioxidant and antiapoptotic pro-
tein decreased at 1.6–2.4 times for treated conditions with 
Ator or MSCs and Ator + MSCs conditions compared with 
non-treated sample (Fig. 6a). The treated conditions with 
Ator + MSCs possessed lowest rate of IL1β compared with 
other treated and non-treated conditions. The tumor micro-
environment due to modulation of inflammatory cytokines 
could regulate brain tumor development and progression. 
The obtained results for IL1β proved tumor supersession 
which could correlated with results of BCL2 and VEGF 
proteins [3, 4, 7, 12].
The GBM tumor cells proliferation was associated with 
KI67 expression. The C6 cells in non-treated cells were 
expressed in 4 fold KI67 which shows proliferation of C6 
cells (Fig. 6a). The utilized Ator, MSCs and combination of 
these components were able to inhibit C6 cell proliferation 
as demonstrated by a significant reduction in KI67 labeling 
index. Interestingly, Ator + MSCs displayed more significant 
Fig. 6  a Quantitative real time-PCR analyses of the mRNA Levels 
of angiogenesis markers (VEGF and BDGF), anti-apoptotic genes 
(BCL2 and GFAP) and pro-apoptotic genes (BAX, IL1ß and KI67) 
for C6 cells with in groups in various experimental groups. b Quanti-
tative analyses of tumor volume a and relative tumor weight c of the 
rats in groups in various experimental groups. The p-value parameter 
showed the level of significant differences as. *p < 0.05, **p < 0.01, 
and # p > 0.05
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impact on cellular proliferation and KI67 expression index 
did not changed compared with initial condition. These 
results for KI67 indexes for experimental conditions could 
be correlated with cellular growth inhibition measurements 
[3, 4, 7, 12, 34].
In vivo analysis
The in vivo study on the C6 induced GBM rat models have 
cleared that co-administration of Ator with MSCs could 
significantly increase the animal’s median survival. More-
over, we could detect an abruptly improving the survival 
of the Ator as well as MSCs treated animals. In following 
we investigated the antitumor efficacy of Ator and MSCs 
in implanted GBM tumor model in rats. The experimental 
implementation scheme was shown in Fig. 1. As can be seen 
from Fig. 6b, for the PBS treated group (Control), the tumor 
grew rapidly and its size was highest level compared with 
other groups. Meanwhile, the Ator and MSCs treated groups 
showed superior tumor suppressive outcome. Interestingly, 
the tumor growth of animals treated with simultaneous uti-
lization of Ator and MSCs condition (Ator + MSCs) was 
dramatically inhibited and the size of tumor was notably 
smaller than other treated groups. In the same way, as shown 
in Fig. 6c, the average tumor weight of the treated condition 
was remarkably smaller than other conditions. The obtained 
results indicated the satisfactory antitumor effect of Ator and 
MSCs for GBM model [3, 8, 9, 21, 23]. The simultaneous 
utilization of Ator and MSCs condition presented superior 
antitumor efficacy than non-treated condition and single 
treated animals with Ator or MSCs.
H&E staining
Following the underlying antitumor mechanism of Ator and 
MSCs were analyzed by H&E staining and histological anal-
yses of tumor tissues of each conditions. Glomeruloid struc-
ture as bizarre form of endothelial proliferation observed 
for non-treated condition (Control). These structures com-
prise capillary tufts (black arrow) which dispersed amidst 
a proliferation of endothelial cells and pericytes associated 
with necrosis as well as congestion and hemorrhage region 
(Fig. 7a).
The several phenomena including pseudopalisading with 
moderate necrosis of neoplastic cells, small vessels distin-
guish the normal vasculature associated with dark neuron, 
existence of higher number of microglia cells and moderate 
cellularity of tumoral cells validate anti-angiogenesis and 
apoptotic activity of Ator on GBM in the rat model (Control) 
(Fig. 7b). Moreover, the moderate pseudopalisading necro-
sis of neoplastic cells along with growth of microvascular 
and glomeruloid structures distributed amidst a proliferation 
of endothelial cells and pericytes which observed in non-
treated condition (Control) (Fig. 7c). As shown in Fig. 7d 
and e in Ator group the moderate pseudopalisading necrosis 
of neoplastic cells, and formation of small delicate vessels 
representing vascularity in normal form which associated 
with dark microglia cell and moderate cellularity of tumoral 
cells in this group. For MSCs goup, this glioblastoma has 
presented high cellularity, with mild hyperchromatism as 
well as pleomorphism of cells and nuclei. Besides, the vas-
cularity as well as necrosis region with neoplastic cells pali-
sading around it observed for MSCs treated group (Fig. 7f). 
In addition, existence of the cellularity, hyperchromatism, 
pleomorphic neoplastic cells, multi-nucleoli and high 
mitotic index and calcification displayed for MSCs group. 
Interstingly, in Ator + MSCs group the low hypercellu-
larity and mitosis index as well as mild level of invasive 
tumor cells show a predilection for perivascular cuffing and 
inflammation around a blood vessel without pseudopalisad-
ing necrosis (Fig. 7h). Morever, glomeruloid structure and 
mild or limited invasive tumoral cell density accompanied 
with proliferation of microvascular without pseudopalisad-
ing necrosis were indicative in Ator + MSCs group (Fig. 7i).
The anti-angiogenesis and apoptotic activity of Ator 
against GBM cell line has been previously reported by Bayat 
et al. [3]. In MSCs group, low hypercellularity and mitosis 
index as well as mild invasive of tumor cells without pseu-
dopalisading necrosis indicate that the anticancer effect of 
MSCs in a rat model of GBM. It has been shown that by 
means of tumour-specific tropism of MSCs can be trans-
duced to deliver anticancer agents such as interleukins (IL-2, 
IL-7, IL-18, and IL-12), TRAIL, and interferon (IFN-β and 
IFN-γ) directly to glioma sites to kill tumour cells or to regu-
late immune responses [2, 4, 35, 36]. Mild or limited inva-
sive tumoral cells associated with low microvascular prolif-
eration without pseudopalisading necrosis, in Ator + MSCs 
group shows that simultaneous utilization of MSCs and Ator 
can exert more anticancer activity against GBM rather than 
MSCs and Ator alone in experimental GBM model.
Conclusions
Whether adding Ator and MSCs could improve anti-tum-
origenicity in glioblastma tumor and inhibit tumor cell 
proliferation was evaluated in vitro and in vivo studies. It 
could be demonstrated that the co-treatment of Ator with 
MSCs could augment the cytotoxic effects of Ator on the 
C6 cell lines. Their multipotency, pro-regenerative effects, 
immunoregulatory and their chemotactic properties to home 
to tumor invaded regions make them a good candidate for 
cancer therapy.
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Fig. 7  Histopathology of glioblastoma-driven brain tumors. Hema-
toxylin and eosin staining of brain slice with colored boxes highlight-
ing areas of particular interest for non-treated condition. a, b and c 
Non-treated condition, d and e Ator group, f and g MSCs group and 
h and i MSCs + Ator group. a Glomeruloid structure is a bizarre 
form of endothelial proliferation that comprise capillary tufts (black 
arrow) dispersed amidst a proliferation of endothelial cells and peri-
cytes merged with necrosis, congestion and hemorrhage, b Pseudo-
palisading of neoplastic cells (black arrow) with severe necrosis (star) 
associated with microvascular proliferation (green arrow), c Pseudo-
palisading with moderate necrosis of neoplastic cells (black arrow) 
along with microvascular proliferation (green arrows), glomeruloid 
structures (arrows) dispersed amidst of endothelial cells and peri-
cytes. d Pseudopalisading with moderate necrosis of neoplastic cells 
(black arrow), e small delicate vessels characterize the normal vas-
culature associated with dark neuron (green arrow), microglia cell 
(arrow head) and moderate cellularity of tumoral cells. f This glio-
blastoma has manifest cellularity, with noticeable hyperchromatism 
as well as pleomorphism. Note the prominent vascularity and the area 
of necrosis with neoplastic cells palisading around it, g marked cel-
lularity, with marked hyperchromatism, pleomorphic neoplastic cells, 
multi-nucleoli and (arrow head), high mitotic index and calcification, 
Inset: four mitosis phases in control group, inset: high mitotic index 
associated with various mitotic figures including prophase (blue 
arrow head), metaphase (black arrow head) and anaphase (red arrow 
head. h Low hypercellularity (arrow head), low mitosis index and 
mild invasive tumor cells (arrow) show a predilection for perivascular 
cuffing without pseudopalisading necrosis, Inset: normal neuron and 
small delicate vessels; i Glomeruloid (black arrow) and mild or lim-
ited invasive tumoral cells associated with microvascular prolifera-
tion (green arrows) without pseudopalisading necrosis. (Color figure 
online)
7795Molecular Biology Reports (2020) 47:7783–7795 
1 3
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Charles NA et al (2011) The brain tumor microenvironment. Glia 
59(8):1169–1180
 2. Abdi Z, Eskandary H, Nematollahi-Mahani SN (2017) Induction of 
human glioma tumor in Sprague-Dawley rats with intact immune 
system. Turk Neurosurg 27(5):716–724
 3. Bayat N et al (2018) The anti-angiogenic effect of atorvastatin in 
glioblastoma spheroids tumor cultured in fibrin gel: in 3D in vitro 
model. Asian Pac&nbsp;J Cancer Prev 19(9):2553
 4. Li C et al (2019) An investigation on the cytotoxicity and caspase-
mediated apoptotic effect of biologically synthesized gold nanopar-
ticles using Cardiospermum halicacabum on AGS gastric carcinoma 
cells. Int J Nanomed 14:951
 5. Arvold ND, Reardon DA (2014) Treatment options and outcomes 
for glioblastoma in the elderly patient. Clin Interv Aging 9:357
 6. Pacioni S et al (2017) Human mesenchymal stromal cells inhibit 
tumor growth in orthotopic glioblastoma xenografts. Stem Cell Res 
Ther 8(1):1–15
 7. Garnier D et al (2019) Glioblastoma stem-like cells, metabolic strat-
egy to kill a challenging target. Front Oncol 9:118
 8. Sakariassen P, Immervoll H, Chekenya M (2007) Cancer stem cells 
as mediators of treatment resistance in brain tumors: status and con-
troversies. Neoplasia (New York, NY) 9(11):882
 9. Fan Z et al (2016) Atorvastatin partially inhibits the epithelial-mes-
enchymal transition in A549 cells induced by TGF-β1 by attenuating 
the upregulation of SphK1. Oncol Rep 36(2):1016–1022
 10. Ohlsson LB et al (2003) Mesenchymal progenitor cell-mediated 
inhibition of tumor growth in vivo and in vitro in gelatin matrix. 
Exp Mol Pathol 75(3):248–255
 11. Landen JW et  al (2004) Noscapine crosses the blood-brain 
barrier and inhibits glioblastoma growth. Clin Cancer Res 
10(15):5187–5201
 12. Nakamura K et al (2004) Antitumor effect of genetically engi-
neered mesenchymal stem cells in a rat glioma model. Gene Ther 
11(14):1155–1164
 13. Blum R et al (2005) Ras inhibition in glioblastoma down-regulates 
hypoxia-inducible factor-1α, causing glycolysis shutdown and cell 
death. Cancer Res 65(3):999–1006
 14. Boudreau DM, Yu O, Johnson J (2010) Statin use and cancer risk: 
a comprehensive review. Exp Opin Drug Saf 9(4):603–621
 15. Dulak J, Józkowicz A (2005) Anti-angiogenic and anti-inflammatory 
effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug 
Targets 5(8):579–594
 16. Kamat AM, Nelkin GM (2005) Atorvastatin: a potential chemopre-
ventive agent in bladder cancer. Urology 66(6):1209–1212
 17. Floros KV et al (2006) Alterations in mRNA expression of apop-
tosis-related genes BCL2, BAX, FAS, caspase-3, and the novel 
member BCL2L12 after treatment of human leukemic cell line 
HL60 with the antineoplastic agent etoposide. Ann NY Acad Sci 
1090(1):89–97
 18. Valdés-Rives SA et al (2017) Apoptotic signaling pathways in 
glioblastoma and therapeutic implications. BioMed Res Int 
2017:7403747
 19. He Z et al (2012) Cell killing and radiosensitizing effects of ator-
vastatin in PC3 prostate cancer cells. J Radiat Res 53(2):225–233
 20. Çiftçi GA, Işcan A, Kutlu M (2015) Escin reduces cell prolifera-
tion and induces apoptosis on glioma and lung adenocarcinoma 
cell lines. Cytotechnology 67(5):893–904
 21. Bayat N et al (2016) Apoptotic effect of atorvastatin in glioblas-
toma spheroids tumor cultured in fibrin gel. Biomed Pharmacother 
84:1959–1966
 22. Xie Z, Chin LS (2008) Molecular and cell biology of brain tumor 
stem cells: lessons from neural progenitor/stem cells. NeuroSurg 
Focus 24(3–4):E25
 23. Kosztowski T, Zaidi HA, Quiñones-Hinojosa A (2009) Applica-
tions of neural and mesenchymal stem cells in the treatment of 
gliomas. Expert Rev Anticancer Ther 9(5):597–612
 24. Quail DF, Joyce JA (2013) Microenvironmental regulation of 
tumor progression and metastasis. Nat Med 19(11):1423
 25. Dietrich J, Imitola J, Kesari S (2008) Mechanisms of disease: the 
role of stem cells in the biology and treatment of gliomas. Nat 
Clin Pract Oncol 5(7):393–404
 26. Nooshabadi VT et al (2020) Impact of atorvastatin loaded exo-
some as an anti-glioblastoma carrier to induce apoptosis of 
U87 cancer cells in 3D culture model. Biochem Biophys Rep 
23:100792
 27. Bordbar S et al (2020) Production and evaluation of decellularized 
extracellular matrix hydrogel for cartilage regeneration derived 
from knee cartilage. J Biomed Mater Res Part A 108(4):938–946
 28. Khanmohammadi M et al (2019) Multipotency expression of 
human adipose stem cells in filament-like alginate and gelatin 
derivative hydrogel fabricated through visible light-initiated 
crosslinking. Mater Sci Eng C 103:109808
 29. Khanmohammadi M, Sakai S, Taya M (2017) Impact of immo-
bilizing of low molecular weight hyaluronic acid within gela-
tin-based hydrogel through enzymatic reaction on behavior of 
enclosed endothelial cells. Int J Biol Macromol 97:308–316
 30. Zahiri M et al (2019) Encapsulation of curcumin loaded chitosan 
nanoparticle within poly (ε-caprolactone) and gelatin fiber mat 
for wound healing and layered dermal reconstitution. Int J Biol 
Macromol 153:1241
 31. Shafei S et al (2020) Exosome loaded alginate hydrogel promotes 
tissue regeneration in full-thickness skin wounds: an in vivo study. 
J Biomed Mater Res 108(3):545–556
 32. Astaneh ME et al (2020) Chitosan/gelatin hydrogel and endo-
metrial stem cells with subsequent atorvastatin injection impact 
in regenerating spinal cord tissue. J Drug Deliv Sci Technol 
58:101831
 33. Morrone FB et al (2006) In vivo glioblastoma growth is reduced 
by apyrase activity in a rat glioma model. BMC Cancer 6(1):226
 34. Abbas M, Kausar S, Cui H (2019) Therapeutic potential of natural 
products in glioblastoma treatment: targeting key glioblastoma 
signaling pathways and epigenetic alterations. Clin Transl Oncol 
22:1–15
 35. Du J et al (2019) The different effects of IFN-β and IFN-γ on 
the tumor-suppressive activity of human amniotic fluid-derived 
mesenchymal stem cells. Stem cells int 2019:4592071
 36. Zhang Q et al (2018) Current status and potential challenges of 
mesenchymal stem cell-based therapy for malignant gliomas. 
Stem Cell Res Ther 9(1):228
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
